Investors rebuff Celldex's METRICs

Celldex Therapeutics Inc. (NASDAQ:CLDX) shed $3.48 (21%) to $13.10 on Wednesday on changes to the pivotal Phase II METRIC study of glembatumumab vedotin to treat metastatic triple-negative breast cancers (TNBC) that overexpress glycoprotein NMB ( GPNMB). The company now believes enrollment will extend into 2016.

Celldex said trial sites are telling the company "that previously established eligibility criteria are limiting their ability to enroll patients they feel are clinically appropriate on study." ...